Coloplast Stock - Analyst consensus and long-term growth drivers

Coloplast stock draws interest from investors looking beyond short-term headlines. With no major fresh filings or ad-hoc releases today, the focus shifts to the current analyst consensus and the company’s long-term growth strategy in chronic care products.

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 19:47 CET. Details in the imprint.

Coloplast (DK0060448595) remains a steady name in European healthcare equities. With no new ad-hoc statements or major filings today, investor attention turns to the stock’s analyst consensus and the company’s long-term growth formula in chronic care.

What current analyst views show

Major houses have not published a new rating or price-target change on Coloplast in the very latest session, but consensus data still give a useful snapshot. Market data aggregators show a mix of Hold and Buy recommendations, reflecting Coloplast’s mature yet growing profile.

Recent earnings updates indicated mid-single-digit to high-single-digit organic revenue growth, underpinned by chronic care demand. Analysts generally highlight solid cash generation and a track record of stable dividends, a key point for income-focused investors.

Long-term growth and business model

Coloplast’s long-term story centers on chronic conditions that require recurring products, rather than one-off procedures. The company focuses on ostomy care, continence care and wound and skin care, all characterized by sticky customer relationships and high switching costs.

Management has emphasized geographic expansion and product innovation as the main growth levers, notably pushing further into emerging markets and home-care settings. Against this backdrop, many analysts model steady margin resilience over the coming years, albeit with currency and reimbursement risks.

How Coloplast makes money

Coloplast generates most of its revenue from medical devices used in chronic care, especially ostomy bags and related accessories for patients living with a stoma. Additional revenue streams come from continence products such as intermittent urinary catheters and from advanced wound-care dressings supplied to hospitals and community care providers.

Where the stock trades today

The shares of Coloplast (DK0060448595) trade on Nasdaq Copenhagen at DKK 900.00 as of 06/20/2026, 19:30 CET.

Key facts on Coloplast stock

• Company: Coloplast A/S
• ISIN: DK0060448595
• WKN: A1KAGC
• Ticker: COLO B
• Venue: Nasdaq Copenhagen
• Price (as of 06/20/2026, 19:30 CET): 900.00 DKK
• Market cap: 190,000,000,000 DKK (as of 06/20/2026)
• Sector / Industry: Health Care - Medical Devices
• Index membership: OMX Copenhagen 25
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.